Wang W - Search Results

1

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.

Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators. Sandborn WJ, et al. Among authors: wang w. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485-93.e2. doi: 10.1016/j.cgh.2014.01.029. Epub 2014 Jan 27. Clin Gastroenterol Hepatol. 2014. PMID: 24480677 Clinical Trial.

2

Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.

Jharap B, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. Jharap B, et al. Among authors: wang w. Aliment Pharmacol Ther. 2015 Nov;42(9):1082-92. doi: 10.1111/apt.13387. Epub 2015 Sep 3. Aliment Pharmacol Ther. 2015. PMID: 26381802 Free PMC article.

3

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.

Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Panés J, et al. Among authors: wang w. Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16. Gut. 2017. PMID: 28209624 Free PMC article. Clinical Trial.

4

Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.

Panés J, D'Haens GR, Higgins PDR, Mele L, Moscariello M, Chan G, Wang W, Niezychowski W, Su C, Maller E. Panés J, et al. Among authors: wang w. Aliment Pharmacol Ther. 2019 Feb;49(3):265-276. doi: 10.1111/apt.15072. Aliment Pharmacol Ther. 2019. PMID: 30663107 Free PMC article. Clinical Trial.

5

Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.

Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Panaccione R, et al. Among authors: wang w, wang l. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Dig Dis Sci. 2021. PMID: 32816215 Free PMC article. Clinical Trial.

6

Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.

Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. Sandborn WJ, et al. Among authors: wang w. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1821-1830.e3. doi: 10.1016/j.cgh.2020.10.038. Epub 2020 Oct 27. Clin Gastroenterol Hepatol. 2022. PMID: 33127596 Free article. Clinical Trial.

7

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.

Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J. Vermeire S, et al. Among authors: wang w. J Crohns Colitis. 2021 Jul 5;15(7):1130-1141. doi: 10.1093/ecco-jcc/jjaa249. J Crohns Colitis. 2021. PMID: 33290538 Free PMC article. Clinical Trial.

8

Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.

Panés J, Vermeire S, Dubinsky MC, Loftus EV, Lawendy N, Wang W, Salese L, Su C, Modesto I, Guo X, Colombel JF. Panés J, et al. Among authors: wang w. J Crohns Colitis. 2021 Nov 8;15(11):1852-1863. doi: 10.1093/ecco-jcc/jjab065. J Crohns Colitis. 2021. PMID: 33884415 Free PMC article.

9

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.

Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Sandborn WJ, et al. Among authors: wang w. Aliment Pharmacol Ther. 2022 Feb;55(4):464-478. doi: 10.1111/apt.16712. Epub 2021 Dec 1. Aliment Pharmacol Ther. 2022. PMID: 34854095 Free PMC article.

10

Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program.

Sandborn WJ, Sands BE, Vermeire S, Leung Y, Guo X, Modesto I, Su C, Wang W, Panés J. Sandborn WJ, et al. Among authors: wang w. Therap Adv Gastroenterol. 2022 Dec 5;15:17562848221136331. doi: 10.1177/17562848221136331. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 36506749 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89,457 results

Search Page

Filters